Get the content you want anytime you want.

MRSA-eliminating Bacteria Found Within the Human Body

JUL 29, 2016 | KRISTI ROSA

Lugdunin and MRSA-elimination

In their article, the study authors wrote, "To investigate whether the presence of S. lugdunensis in the human nose can prevent co-colonization by S. aureus, we examined nasal swabs from 187 hospitalized patients for colonization by S. lugdunensis, S. aureus or both." Their findings revealed that patients who naturally carried S. lugdunesis within their noses were six times less likely to be S. aureus carriers than those who did not have S. lugdunesis. In a 30-day test tube trial, researchers found that S. aureus bacteria were not able to achieve resistance against lugdunin. These findings suggest that lugdunin prohibits colonization by S. aureus, and thus, can be developed into a valuable antibiotic, which can be used to prevent staphylococcal infections.

Peschel’s team’s original aim was to study S. aureus within the nose in order to better understand how the bacterium functions. After screening 90 bacteria from the nose, they found that S. lugdunensis was the only one that could eliminate MRSA, and in addition, kill other strains of S. aureus that were resistant to several antibiotics, such as glycopeptide.

In a follow-up experiment, Peschel and his team applied S. aureus to the skin of mice and found that the treatment with lugdunin strongly reduced or eliminated S. aureus on the surface of the skin and within the deeper layers of the skin. Since the nasal cavity contains the strongest risk of S. aureus, Peschel closely examined the effects of introducing S. lugdunesis into the noses of cotton rats where he found that lugdunin had reduced S. aureus colonization.

Peschel aims to develop lugdunin into an antibiotic for human use.

Kim Lewis, a microbiologist at Northeastern University in Boston, Massachusetts said in an article, “It’s the first time researchers have been able to definitively connect the production of an antibiotic in a bacterium with the suppression of a competitor in a microbiome community.”
To stay informed on the latest in infectious disease news and developments, please sign up for our weekly newsletter.

Big advances in treatment can